MPL and autoimmune thrombocytopenic purpura: Since these studies were conducted before newer agents such as thrombopoietin receptor agonists (TPO-RA) became broadly available, it would be important to continue assessing the trends of ICH in patients with ITP to understand the impact of these medications on reducing the incidence of ICH [24,25].